ArticleNature biotechnology2026
Discovery and design of potent cell surface display elements.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell surface display (CSD) elements are a major class of bioengineering modules, but systematic rules linking CSD sequence to functional potency are lacking. Here we develop DeepSCan, a suite of deep learning and artificial intelligence models to systematically map CSD sequence-function relationships to reliably capture potent elements' conserved features and iteratively design and develop potent de novo CSD modules for mRNA antigen display. We experimentally quantify surface expression across >570 chimeric antigens, derive cell surface translocation strength labels for ~310 CSD elements and compile ~45 independent training datasets. We train three generations of DeepSCan models and evaluate their performance. Guided by these models, we computationally design 3,700 and experimentally validate approximately 120 generative CSDs, identifying 7 generative CSDs that match or exceed the cell surface translocation strength of the most potent naturally occurring CSDs. Enhanced surface displays are validated across multiple cell types and are functional in an antigen-specific CAR-T cytotoxicity assay.
Identifiers
42587137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.